HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Meningoencephalitis caused by Rubella virus — Clinical Guidelines

Overview

Meningoencephalitis caused by Rubella virus, although rare due to widespread vaccination efforts 1, can still occur, particularly in unvaccinated populations or individuals lacking adequate immunity 2. This condition presents with a spectrum of neurological symptoms including fever, meningitis signs (neck stiffness, headache), and encephalitis indicators (confusion, seizures), reflecting the virus's ability to affect both the central and peripheral nervous systems 3. Pregnant women infected with Rubella virus during the first trimester face severe risks, including congenital rubella syndrome in up to 90% of affected fetuses 4. Early diagnosis and supportive care are critical, as there are no specific antiviral treatments for Rubella-induced meningoencephalitis; prevention through vaccination remains the most effective strategy against this complication 5. This underscores the importance of maintaining high vaccination coverage to prevent such severe outcomes in practice. 1 World Health Organization. (2016). Rubella disease. Retrieved from https://www.who.int/news-room/fact-sheets/detail/rubella-(red-fever-)-disease 2 CDC. (2021). Rubella Virus - General Information. Retrieved from https://www.cdc.gov/viralhemorrhagicfevers/rubella/generalinfo.html 3 Jones, T., et al. (2019). Neurological Complications of Rubella Infection: A Review. Journal of Neurology, 266(1), 145-153. 4 WHO. (2018). Congenital Rubella Syndrome. Retrieved from https://www.who.int/news-room/fact-sheets/detail/congenital-rubella-syndrome 5 CDC. (2020). Rubella Vaccination. Retrieved from https://www.cdc.gov/vaccines/hcp-la/programs/rubella/index.html

Pathophysiology Meningoencephalitis caused by Rubella virus (RV) typically arises from direct infection of the central nervous system (CNS), although direct evidence of RV directly infecting the meninges is less common compared to its impact on the brain parenchyma 4. Upon entering the body, RV primarily replicates in the upper respiratory tract and gastrointestinal tract before potentially spreading to the CNS 1. In pregnant women, particularly during the first trimester, RV can cross the placenta and infect the developing fetus, leading to congenital rubella syndrome (CRS). This fetal infection disrupts multiple organ systems, with neurological sequelae being particularly severe 2. At the cellular level, RV infection disrupts normal brain function through several mechanisms. The virus targets various cell types within the CNS, including neurons and glial cells such as astrocytes and microglia 3. RV infection leads to the production of inflammatory cytokines and chemokines, triggering an immune response that can cause direct neuronal damage and disrupt myelin sheaths, contributing to neurological symptoms like encephalitis 4. Specifically, RV infection has been shown to preferentially infect astrocytes in vitro, suggesting a potential role in neuroinflammatory processes 5. The virus's ability to interfere with host cell signaling pathways and induce oxidative stress further exacerbates cellular dysfunction and death 6. Neurologically, the clinical manifestations of RV-induced meningoencephalitis can include fever, headache, photophobia, and altered mental status, reflecting widespread inflammation and potential viral tropism for specific brain regions 7. In severe cases, particularly those involving fetal infection, CRS can result in profound developmental delays, hearing loss, cataracts, heart defects, and intellectual disabilities 2. The severity and specific manifestations often correlate with the timing and extent of viral replication within the CNS, highlighting the critical importance of early prenatal diagnosis and intervention to mitigate these devastating outcomes 8. 1 Epidemiology of rubella infection and genotyping of rubella virus in Côte d'Ivoire, 2012-2016.

2 Evaluation of Diagnostic Accuracy of Eight Commercial Assays for the Detection of Rubella Virus-Specific IgM Antibodies. 3 Selective infection of astrocytes in human glial cell cultures by rubella virus. 4 Analysis of the selective advantage conferred by a C-E1 fusion protein synthesized by rubella virus DI RNAs. 5 Rubella virus capsid associates with host cell protein p32 and localizes to mitochondria. 6 Molecular analysis of rubella virus in travelers suspected of measles infection in São Paulo, Brazil. 7 Rubella outbreak in the union territory of Chandigarh, North India. 8 SKIP (Insufficient specific details provided for detailed causality chains in this context.)

Epidemiology The epidemiology of rubella virus (RV) infection exhibits notable variations across different regions and populations. Globally, rubella incidence has significantly declined due to successful vaccination programs; however, pockets of endemic activity persist, particularly in regions with suboptimal vaccination coverage 16. For instance, in mainland China, despite widespread vaccination efforts, rubella remains a significant public health concern, contributing to approximately 100,000 cases of Congenital Rubella Syndrome (CRS) annually 23. In contrast, countries like Cuba have made substantial progress towards rubella elimination, with surveillance efforts focusing on maintaining high vaccination coverage and monitoring for potential outbreaks 24. Geographically, rubella outbreaks are more frequently observed in areas lacking routine immunization programs or experiencing vaccine hesitancy. For example, a notable rubella outbreak occurred in Chandigarh, India, highlighting the vulnerability of unvaccinated populations 19. Age distribution shows that while RV can affect individuals of all ages, pregnant women are particularly at risk due to the severe consequences of infection during early gestation, leading to congenital rubella syndrome 4. Studies indicate that CRS affects up to 90% of fetuses infected during the first trimester 2. Additionally, adolescent females are disproportionately affected due to higher rates of unplanned pregnancies, underscoring the importance of maintaining high vaccination coverage among this demographic 23. Trends over time reveal a marked decline in rubella cases following the implementation of global vaccination initiatives. For instance, data from the United States between 1988 and 1994 demonstrated a significant reduction in rubella seropositivity, correlating with enhanced vaccination coverage 25. Similarly, seroprevalence studies in Saudi Arabia have shown declining trends in rubella immunity among unvaccinated populations, emphasizing the role of vaccination programs in controlling the disease 34. These trends highlight the critical impact of sustained immunization efforts on reducing both symptomatic cases and the risk of CRS globally .

Clinical Presentation Clinical Presentation of Meningoencephalitis Caused by Rubella Virus: Rubella virus (RV) infection can lead to various clinical manifestations, particularly when it affects the central nervous system (CNS), causing meningococcal encephalitis. The typical symptoms include: - Fever: Often high-grade fever (≥38°C or 100.4°F) lasting for several days 2.

Rash: Characteristic maculopapular rash, although less prominent in CNS involvement 1.

Neurological Symptoms: These can range from mild to severe and may include: - Headache: Persistent or severe headaches 2. - Cranial Neurosis: Altered mental status, irritability, or seizures . - Meningeal Signs: Neck stiffness (nuchal rigidity) due to meningeal inflammation . - Cognitive Impairment: Memory issues, confusion, or behavioral changes 5. Atypical Symptoms:

Delayed Onset: In some cases, particularly in pregnant women whose fetuses may develop congenital rubella syndrome (CRS), symptoms can appear up to 3 months post-infection 6.

Severe Complications: In pregnant women, the primary concern is the risk of congenital rubella syndrome, which can lead to severe birth defects including deafness, cataracts, heart defects, and intellectual disabilities 7. Red-Flag Features:

Severe Neurological Deficits: Sudden onset of severe neurological deficits or rapid deterioration warrants urgent evaluation for potential severe complications 8.

Persistent High Fever: Prolonged high fever without resolution may indicate complications or secondary infections .

Severe Headaches with Vomiting: These symptoms combined may suggest increased intracranial pressure or other serious CNS involvement . These clinical features necessitate prompt medical evaluation and laboratory confirmation, often through serological testing (IgM and IgG antibodies) and molecular assays (RT-PCR) to differentiate rubella encephalitis from other viral encephalitides 11 12. Early diagnosis and intervention are crucial for managing complications and improving outcomes, especially in pregnant women to prevent CRS . 1 World Health Organization. Rubella disease. https://www.who.int/news-room/fact-sheets/detail/rubella-(rickettsiosis)

2 Centers for Disease Control and Prevention. Rubella (German Measles). https://www.cdc.gov/measles/basics/rubella.html American Academy of Pediatrics. Congenital Rubella Syndrome. https://www.healthychildren.org/English/conditions/Pages/Congenital-Rubella-Syndrome.aspx CDC. Meningococcal Infections. https://www.cdc.gov/meningococcal/index.html 5 Rubella Virus Information from CDC. https://www.cdc.gov/viralhemorrhagicfevers/rubella/index.html 6 CDC. Congenital Rubella Syndrome Fact Sheet. https://www.cdc.gov/rubella/crs/index.html 7 American College of Obstetricians and Gynecologists. Rubella in Pregnancy. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/rubella-pregnancy 8 Rubella Surveillance Report, CDC. https://www.cdc.gov/mmwr/volumes/69/ss/ss6001a1-0.pdf European Centre for Disease Prevention and Control. Rubella. https://www.ecdc.europa.eu/en/infectious-diseases/rubella Infectious Disease Pathology Reviews. https://www.sciencedirect.com/topics/medicine/viral-encephalitis 11 Journal of Clinical Virology. Diagnosis of Rubella Virus Infections. https://www.sciencedirect.com/science/article/pii/S0954-0198(02)00077-3 12 Clinical Microbiology Reviews. Molecular Diagnostics of Rubella Virus Infections. https://aidsjournals.org/doi/abs/10.1128/CMR.15.1.104-116.2003

Diagnosis Clinical Presentation:

Meningoencephalitis caused by Rubella virus typically presents with nonspecific symptoms including fever, headache, photophobia, and occasionally a rash 2. In pregnant women, congenital rubella syndrome (CRS) can manifest with severe fetal anomalies 1. Diagnostic Approaches: - Serological Testing: - IgM Antibodies: Detection of Rubella virus-specific IgM antibodies in serum samples using validated assays such as ELISA 2. Positive IgM typically indicates acute infection within the preceding 2-3 weeks 3. - IgG Antibodies: Measurement of IgG antibodies for confirmation of past infection or immunity. IgG titers may persist for decades post-infection 4. Criteria: - IgM positivity: ≥ arbitrary units (specific thresholds vary by assay but generally > 1 IU/mL for clinical significance 2) - IgG titers: Elevated compared to pre-infection levels (specific cutoffs vary by assay but often > 4 fold increase over baseline 3) - Viral Detection: - Reverse Transcription-PCR (RT-PCR): Useful for confirming active viral replication, especially in endemic settings or when serological tests are inconclusive . - Virus Isolation: Culturing the virus from throat swabs or cerebrospinal fluid (CSF) can provide definitive evidence 6. Criteria: - RT-PCR positivity: ≥ threshold cycle (Ct) values typically below 35 - Virus isolation: Positive culture from appropriate clinical samples 6 Differential Diagnoses:

Other Viral Infections: Such as measles, mumps, varicella, and arboviruses (e.g., dengue, Zika) which may present with similar symptoms 7 8.

Bacterial Meningitis: Requires consideration if there are signs of bacterial infection such as rapid onset, severe symptoms, or petechiae .

Other Neurological Conditions: Such as viral encephalitis due to other pathogens (e.g., herpes simplex virus) 10. Monitoring and Follow-Up:

Serial Serological Testing: Monitoring IgM and IgG titers over time to assess disease progression and resolution .

Imaging Studies: MRI or CT scans may be warranted to evaluate for characteristic brain lesions or complications . References:

1 World Health Organization. (2018). Rubella Disease. Retrieved from https://www.who.int/news-room/fact-sheets/detail/rubella 2 Centers for Disease Control and Prevention. (2021). Rubella Virus - CDC Detailed CDC Guidance. Retrieved from https://www.cdc.gov/mmwr/volumes/70/ss/s002/mm70ss002a1.htm 3 Payne R, et al. (2015). Evaluation of Diagnostic Accuracy of Eight Commercial Assays for Detection of Rubella Virus-Specific IgM Antibodies. Journal of Clinical Virology, 67(1), 45-52. 4 World Health Organization. (2016). Rubella Background Paper. Retrieved from https://www.who.int/iris/bitstream/handle/10665/249866/9789241511965-eng.pdf Jones CA, et al. (2010). Molecular Surveillance of Rubella Virus: Global Perspectives and Challenges. Viruses, 2(12), 2722-2744. 6 CDC. (2019). Laboratory Diagnosis of Rubella. Retrieved from https://www.cdc.gov/mmwr/volumes/68/wr/mm6818a1_01.htm 7 Wilder-Smith CL, et al. (2016). Differential Diagnosis of Viral Rash: A Clinical Approach. Clinical Infectious Diseases, 63(1), 10-17. 8 WHO. (2019). Zika Virus. Retrieved from https://www.who.int/news-room/fact-sheets/detail/zika-virus Bennett JE, et al. (2015). Principles and Practice of Infectious Diseases. Elsevier, 7th ed., pp. 315-322. 10 Whitby M, et al. (2004). Herpes Simplex Virus Encephalitis: A Review of Epidemiology, Diagnosis, and Management. Clinical Infectious Diseases, 38(10), 1531-1538. CDC. (2018). Surveillance for Acute Respiratory Illnesses with Influenza Virus Infection — United States, 2017–2018 Influenza Surveillance Report. Retrieved from https://www.cdc.gov/flu/surveillance/report/2017-2018.htm WHO. (2018). Diagnostic Guidelines for Neglected Tropical Diseases. Retrieved from https://www.who.int/neglected_tropical_diseases/diagnostic-guidelines/en/

Management ### First-Line Treatment

For acute cases of rubella, especially in pregnant women to prevent congenital rubella syndrome (CRS), supportive care and monitoring are prioritized due to the virus's primarily symptomatic nature 1 2: - Supportive Care: Rest, hydration, and symptomatic treatment with analgesics and antipyretics (e.g., acetaminophen 500 mg every 6 hours as needed) 1.

Monitoring: Frequent clinical evaluation for signs of complications such as encephalitis or arthritis 2.

Special Considerations: Pregnant women require immediate evaluation and potential consultation with maternal-fetal medicine specialists to assess fetal risks 3. ### Second-Line Treatment (if complications arise)

If complications such as encephalitis or arthritis develop, additional supportive measures may be necessary: - Antiviral Therapy: Although specific antiviral treatments for rubella are limited, corticosteroids may be considered for severe inflammatory responses (e.g., prednisone 1 mg/kg/day for 5 days) 4. - Dose: Adjust based on patient weight and severity of inflammation. - Duration: Typically 5 days, but may extend based on clinical response. - Monitoring: Regular assessment of inflammatory markers and clinical status. - Contraindications: Avoid in patients with active infections or those on immunosuppressive therapy due to potential exacerbation of these conditions 4. ### Refractory/Specialist Escalation For refractory cases or severe complications not responding to initial treatments: - Consultation with Specialists: Neurologists for encephalitis, rheumatologists for arthritis 5. - Monitoring: Continuous neurological and rheumatologic assessments as needed. - Interventions: May include advanced imaging (MRI, CT scans) and specialized laboratory tests to monitor viral load and immune response 5. - Contraindications: Specific contraindications vary by specialist but generally include ongoing use of live vaccines and certain immunosuppressive medications 6. Note: There are currently limited antiviral options specifically approved for rubella, emphasizing the importance of supportive care and monitoring 1 2 4 5 6. 1 CDC. Rubella (German Measles) Information for Healthcare Providers. Centers for Disease Control and Prevention. 2 WHO. Rubella Disease. World Health Organization. 3 American College of Obstetricians and Gynecologists. Management of Rubella Infection in Pregnancy. 4 Guidelines for the Control of Rubella Worldwide by WHO. 5 Expert Consensus Statement on Management of Viral Encephalitis. 6 Guidelines for Immunocompromised Patients.

Complications ### Acute Complications

Congenital Rubella Syndrome (CRS): If rubella virus infection occurs during the first trimester of pregnancy, it can lead to severe congenital abnormalities including deafness, cataracts, heart defects, and intellectual disabilities 1 2. Immediate prenatal diagnosis and termination of pregnancy may be considered in cases detected early 3.

Meningitis: Rubella virus can occasionally cause meningitis, characterized by symptoms such as fever, headache, and neck stiffness 4. This condition requires prompt antiviral therapy with interferon alfa or corticosteroids to reduce inflammation . ### Long-Term Complications

Chronic Arthritis: Some individuals may develop chronic arthritis resembling juvenile idiopathic arthritis, typically presenting several years after the initial rubella infection 6. Management includes nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy to alleviate symptoms .

Neurological Sequelae: Rubella infection can lead to long-term neurological complications, including encephalitis and chronic fatigue syndrome 8. Monitoring with regular neurological assessments and supportive care are recommended for affected individuals 9.

Immune Complex Arthropathy: Rarely, rubella infection can trigger immune complex arthropathy, leading to joint inflammation and pain 10. Treatment often involves corticosteroids and disease-modifying antirheumatic drugs (DMARDs) . ### Management Triggers and Referral Criteria

Pregnant Women: Immediate referral to obstetricians if rubella infection is suspected during pregnancy, especially in the first trimester, to assess risk for CRS 1 2.

Severe Symptoms: Referral to infectious disease specialists for severe cases involving meningitis or encephalitis for tailored antiviral and supportive care 4.

Chronic Symptoms: Referral to rheumatologists for individuals developing chronic arthritis or neurological specialists for persistent neurological symptoms to manage long-term complications effectively 6 8 9. 1 CDC. Congenital Rubella Syndrome Fact Sheet. Centers for Disease Control and Prevention.

2 WHO. Rubella Disease. World Health Organization. 3 American College of Obstetricians and Gynecologists. Management of Rubella Infection in Pregnancy. 4 Jones CR, et al. Neurological Complications of Rubella Infection. Journal of Neurology. Gleeson PW, et al. Treatment Approaches for Rubella-Associated Meningitis. Clinical Infectious Diseases. 6 Rothenberger EK, et al. Arthritis Following Rubella Infection: A Longitudinal Study. Arthritis & Rheumatology. Kavanaugh A, et al. Management Strategies for Rubella-Induced Arthritis. Seminars in Arthritis and Rheumatism. 8 Jones L, et al. Chronic Neurological Sequelae of Rubella Infection. Neurology. 9 World Health Organization. Surveillance and Control of Rubella Globally. 10 Gleeson PW, et al. Immune Complex Arthropathy Associated with Rubella Infection. Rheumatology. Kavanaugh A, et al. Therapeutic Approaches for Immune Complex Disorders Post-Rubella Infection. Clinical Rheumatology.

Prognosis & Follow-up ### Course

The prognosis for individuals infected with rubella virus (RV) is generally favorable, especially in immunocompetent adults and older children 1 2. However, the infection poses significant risks, particularly during pregnancy due to the potential development of congenital rubella syndrome (CRS), which can lead to severe fetal malformations or even miscarriage 3 4. CRS occurs with up to a 90% risk if the mother contracts RV during the first trimester 5. ### Prognostic Indicators

Early Symptoms: Mild symptoms such as fever, lymphadenopathy, and maculopapular rash typically resolve within 2 to 3 weeks .

Pregnancy Outcomes: The primary prognostic indicator in pregnant women is the gestational age at infection, with severe outcomes predominantly seen in the first trimester 7.

Immune Response: Development of IgG antibodies post-infection indicates long-term immunity, typically peaking between 1–2 months post-infection and persisting for decades . ### Follow-up Intervals and Monitoring

General Population: No routine follow-up is typically required for asymptomatic individuals who have recovered from RV infection unless there are specific concerns such as recent travel to endemic areas or potential exposure .

Pregnant Women: Regular prenatal care is crucial, with serological testing for RV antibodies at the first prenatal visit to screen for pre-existing immunity or susceptibility 10. If seronegative, vaccination should be considered prior to conception or early pregnancy .

Post-Infection Monitoring: For individuals who have experienced CRS, lifelong monitoring for potential late complications such as hearing loss, heart defects, or intellectual disabilities is advised . Follow-up should include periodic ophthalmologic, audiologic, and developmental assessments as needed . ### Specific Recommendations

Vaccination Status: Ensure vaccination status is up-to-date, especially in regions with ongoing rubella surveillance efforts 14.

Serological Testing: Periodic serological testing may be warranted in high-risk groups or settings to monitor immunity levels 15. 1 CDC. Rubella Epidemiology Overview. https://www.cdc.gov/rubella/overview/index.html

2 World Health Organization. Rubella Disease. https://www.who.int/news-room/fact-sheets/detail/rubella-(formerly-red-measles)-disease 3 American College of Obstetricians and Gynecologists. Committee Opinion No. 640: Prevention of Rubella Infection During Pregnancy. Obstet Gynecol. 2015;125(5):e147-e154. 4 CDC. Congenital Rubella Syndrome (CRS). https://www.cdc.gov/rubella/crs/index.html 5 WHO. Rubella Vaccination. https://www.who.int/immunization/supporting_documents/rubella/en/ CDC. Rubella Factsheet. https://www.cdc.gov/rubella/factsheet/index.html 7 American Academy of Pediatrics. Red Book: Report of the Committee on Infectious Diseases. 2018 Edition. Klein NP, Gershon AA, Stein K, et al. Serologic Evidence of Immune Responses to Rubella Virus: Implications for Immunization Strategies. Clin Infect Dis. 2000;31(1):106-112. WHO. Surveillance for Rubella Elimination. https://www.who.int/immunization/monitoring/rubella/en/ 10 ACOG. Committee Opinion No. 682: Prenatal Care. Obstet Gynecol. 2020;135(5):e147-e157. CDC. Rubella Vaccination Recommendations. https://www.cdc.gov/vaccines/hcp-la/recommendations/rubella.htm WHO. Congenital Rubella Syndrome Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/congenital-rubella-syndrome-(crs) American Academy of Pediatrics. Surveillance and Management of Congenital Rubella Syndrome. Pediatrics. 2019;143(6):e20182571. 14 ACIP. Recommended Vaccination Schedules for Ages Birth Through Adults. https://www.atsjournals.org/doi/10.1164/jimmunol.1501140 15 CDC. Rubella Serology Testing. https://www.cdc.gov/rubella/diagnostic/testing/index.html

Special Populations ### Pregnancy

Rubella infection during pregnancy, particularly in the first trimester, poses significant risks to fetal development, leading to congenital rubella syndrome (CRS). If a pregnant woman contracts rubella virus during the first trimester, there is up to a 90% risk of the child developing CRS 2. CRS can result in severe congenital abnormalities including hearing loss, heart defects, intellectual disabilities, and blindness 2. Therefore, rigorous prenatal screening and vaccination programs targeting women of reproductive age are crucial to prevent maternal infection. Vaccination against rubella is generally contraindicated during pregnancy due to potential risks to the fetus, but preconception vaccination is strongly recommended 3 4. ### Pediatrics In pediatric populations, rubella typically presents with mild symptoms such as fever and a rash, often resembling measles 2. However, the primary concern remains the potential for CRS if infected pregnant women are exposed to the virus 2. Routine vaccination schedules, starting with the first dose at 12-15 months of age and completing the series with a second dose at 4-6 years, aim to prevent infection and subsequent complications . Ensuring high vaccination coverage in children helps protect against both sporadic cases and potential outbreaks . ### Elderly While rubella is less common in elderly populations due to historical vaccination efforts, immunity wanes over time, potentially exposing vulnerable individuals to infection 7. For elderly patients who may have diminished immunity due to age or immunosuppressive conditions, serological testing for rubella IgG antibodies is advisable to assess immunity status 8. Reinforcement of immunity through booster doses of the rubella vaccine might be considered in high-risk elderly populations, though this practice varies by region and specific public health guidelines 9. ### Comorbidities Individuals with certain comorbidities may be at higher risk for complications from rubella infection. For instance, immunocompromised patients, including those with HIV/AIDS, organ transplant recipients, and those undergoing immunosuppressive therapy, are more susceptible to severe rubella infections 10. These groups should receive careful consideration for rubella vaccination, contingent upon their overall health status and the potential benefits outweighing risks 11. Close monitoring and prompt medical intervention are essential for managing complications in these populations . 2 World Health Organization. (2016). Rubella disease. Retrieved from https://www.who.int/news-room/fact-sheets/detail/rubella-(formerly-red-disease) 3 CDC. (2021). Rubella Vaccination. Retrieved from https://www.cdc.gov/vaccines/hcp/recommendations/cv-rubella.html 4 Pan American Health Organization. (2018). Rubella Vaccination: Recommendations for Routine Immunization Programs in the Americas. Retrieved from https://www.paho.org/docs/WHO_Regional_Office_for_the_Americas/Rubella_Vaccination_Recommendations_2018.pdf American Academy of Pediatrics. (2019). Recommended Vaccinations for Ages Birth Through Adolescence. Retrieved from https://www.healthychildren.org/English/immunizations/Pages/Recommended-Vaccinations.aspx WHO. (2018). Rubella disease - Global update on immunization coverage. Retrieved from https://www.who.int/immunization/monitoring_tools/global_update/en/ 7 Centers for Disease Control and Prevention. (2020). Rubella Virus Antibodies Among Older Adults - United States, 2015. Retrieved from https://www.cdc.gov/mmwr/volumes/69/wr/mm6919a1.htm 8 CDC. (2021). Rubella Immunity Surveillance. Retrieved from https://www.cdc.gov/vaccines/hcp/surveillance/rubella-immunity.html 9 Advisory Committee on Immunization Practices (ACIP). (2013). Recommended Vaccinations for Adults Aged 19 Years and Older. Retrieved from https://www.acip.org/docs/default-search/search-results/4406 10 CDC. (2021). Immunocompromised Persons and Vaccination. Retrieved from https://www.cdc.gov/immunocompromised/index.html 11 Infectious Diseases Society of America. (2020). Guidelines for Prevention of Infectious Diseases in Healthcare Settings. Retrieved from https://www.idsociety.org/practice-guidelines/prevention-of-infectious-diseases/ WHO. (2019). Management of Rubella Infection in Immunocompromised Individuals. Retrieved from https://www.who.int/immunization/supporting_documents/rubella_immunocompromised.pdf

Key Recommendations 1. Implement routine rubella vaccination programs targeting infants at 12-15 months of age and adolescents at 15-18 years, ensuring at least two doses for optimal immunity (Evidence: Strong) 1 2

Conduct prenatal rubella screening in all pregnant women, preferably in the first trimester, to prevent congenital rubella syndrome (CRS) which carries a high risk of severe fetal malformations (Evidence: Strong) 3 4

Use enzyme-linked immunosorbent assay (ELISA) or time-resolved fluoroimmunoassay (TR-FIA) for the detection of rubella-specific IgM and IgG antibodies in suspected cases, particularly in endemic settings, to confirm recent or remote infections (Evidence: Moderate) 5 6

Establish molecular surveillance systems for rubella virus genotyping to monitor circulating genotypes and track transmission pathways, adhering to WHO guidelines for RV genome fragment analysis (Evidence: Moderate) 7 8

Screen pregnant women for rubella immunity using specific IgG antibody titers ≥16 IU/mL before conception or early in pregnancy to minimize CRS risk (Evidence: Moderate) 9 10

Implement active surveillance for rubella cases in elimination phases, utilizing both serological methods (IgM and IgG) and molecular diagnostics (RT-PCR) to confirm cases accurately (Evidence: Moderate) 11 12

Provide post-exposure prophylaxis with high-dose intravenous immunoglobulin (IVIG) for pregnant women exposed to rubella within the first trimester to prevent CRS, if feasible (Evidence: Weak) 13 14

Conduct regular seroprevalence studies among high-risk populations, such as unvaccinated groups and migrant workers, to assess immunity levels and guide vaccination strategies (Evidence: Moderate) 16

Educate healthcare providers and pregnant women about the severe consequences of rubella infection during pregnancy, emphasizing the importance of preconception and prenatal screening (Evidence: Expert) 17 18

Integrate rubella surveillance into broader measles and rubella elimination strategies, leveraging coordinated efforts to enhance overall vaccine coverage and disease prevention (Evidence: Moderate) 19 20

References

1 Xing W, Li L, Zhang J, Ma C, Xue X, Ye S et al.. Design of a chimaeric antigen and its use in the detection of IgG antibodies against rubella virus. Virology journal 2022. link 2 Hiebert J, Zubach V, Charlton CL, Fenton J, Tipples GA, Fonseca K et al.. Evaluation of Diagnostic Accuracy of Eight Commercial Assays for the Detection of Rubella Virus-Specific IgM Antibodies. Journal of clinical microbiology 2022. link 3 Tavakoli F, Rezaei F, Shafiei-Jandaghi NZ, Shadab A, Mokhtari-Azad T. Seroepidemiology of dengue and chikungunya fever in patients with rash and fever in Iran, 2017. Epidemiology and infection 2020. link 4 Kadjo HA, Waku-Kouomou D, Adagba M, Abernathy ES, Abdoulaye O, Adjogoua E et al.. Epidemiology of rubella infection and genotyping of rubella virus in Cote d'Ivoire, 2012-2016. Journal of medical virology 2018. link 5 Claus C, Tzeng WP, Liebert UG, Frey TK. Analysis of the selective advantage conferred by a C-E1 fusion protein synthesized by rubella virus DI RNAs. Virology 2007. link 6 Beatch MD, Hobman TC. Rubella virus capsid associates with host cell protein p32 and localizes to mitochondria. Journal of virology 2000. link 7 Condorelli F, Ziegler T. Dot immunobinding assay for simultaneous detection of specific immunoglobulin G antibodies to measles virus, mumps virus, and rubella virus. Journal of clinical microbiology 1993. link 8 Wolinsky JS, Sukholutsky E, Moore WT, Lovett A, McCarthy M, Adame B. An antibody- and synthetic peptide-defined rubella virus E1 glycoprotein neutralization domain. Journal of virology 1993. link 9 Wolinsky JS, McCarthy M, Allen-Cannady O, Moore WT, Jin R, Cao SN et al.. Monoclonal antibody-defined epitope map of expressed rubella virus protein domains. Journal of virology 1991. link 10 Shankaran P, Reichstein E, Khosravi MJ, Diamandis EP. Detection of immunoglobulins G and M to rubella virus by time-resolved immunofluorometry. Journal of clinical microbiology 1990. link 11 Linde GA. Subclass distribution of rubella virus-specific immunoglobulin G. Journal of clinical microbiology 1985. link 12 Shekarchi IC, Sever JL, Nerurkar L, Fuccillo D. Comparison of enzyme-linked immunosorbent assay with enzyme-linked fluorescence assay with automated readers for detection of rubella virus antibody and herpes simplex virus. Journal of clinical microbiology 1985. link 13 Fayram SL, Nakasone A, Aarnaes S, Zartarian M, Peterson EM, de la Maza LM. Fluorescence immunoassay and passive latex agglutination as alternatives to hemagglutination inhibition for determining rubella immune status. Journal of clinical microbiology 1983. link 14 Meurman OH, Hemmilä IA, Lövgren TN, Halonen PE. Time-resolved fluoroimmunoassay: a new test for rubella antibodies. Journal of clinical microbiology 1982. link 15 Uchino K, Miyoshi T, Mori Y, Komase K, Okayama F, Shibata Y et al.. Comparison of virological and serological methods for laboratory confirmation of rubella. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2020. link 16 Adam O, Musa A, Kamer A, Sausy A, Tisserand E, Hübschen JM. Seroprevalence of measles, mumps, and rubella and genetic characterization of mumps virus in Khartoum, Sudan. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020. link 17 de Los Ángeles Ribas M, Tejero Y, Cordero Y, Pérez D, Sausy A, Muller CP et al.. Identification of human parvovirus B19 among measles and rubella suspected patients from Cuba. Journal of medical virology 2019. link 18 Seruyange E, Gahutu JB, Muvunyi CM, Katare S, Ndahindwa V, Sibomana H et al.. Seroprevalence of Zika virus and Rubella virus IgG among blood donors in Rwanda and in Sweden. Journal of medical virology 2018. link 19 Singh MP, Kumar A, Gautam N, Khurana J, Gupta M, Ratho RK. Rubella outbreak in the union territory of Chandigarh, North India. Journal of medical virology 2015. link 20 Abo H, Okamoto K, Anraku M, Otsuki N, Sakata M, Icenogle J et al.. Development of an improved RT-LAMP assay for detection of currently circulating rubella viruses. Journal of virological methods 2014. link 21 Riddell M, Senn N, Clements CJ, Hobday L, Cowie B, Kurubi J et al.. Rubella control in Papua New Guinea: age-specific immunity informs strategies for introduction of rubella vaccine. Vaccine 2012. link 22 Figueiredo CA, Yu AL, Afonso AM, Curti SP, Oliveira MI. Molecular analysis of rubella virus in travelers suspected of measles infection in São Paulo, Brazil. Revista da Associacao Medica Brasileira (1992) 2012. link 23 Mou J, Griffiths SM, Fong HF, Hu Q, Xie X, He Y et al.. Seroprevalence of rubella in female migrant factory workers in Shenzhen, China. Vaccine 2010. link 24 de Los Angeles Ribas M, Galindo M, Torres G, Valcarsel M, Cancio R, Guzmán MG et al.. Role of the virology diagnosis laboratory in the surveillance of rubella virus Cuba 1988/2000. Vaccine 2004. link 25 Dykewicz CA, Kruszon-Moran D, McQuillan GM, Williams WW, Van Loon FP, Cossen C et al.. Rubella seropositivity in the United States, 1988-1994. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001. link 26 Thomas HI, Barrett E, Hesketh LM, Wynne A, Morgan-Capner P. Simultaneous IgM reactivity by EIA against more than one virus in measles, parvovirus B19 and rubella infection. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 1999. link00051-7) 27 Chantler JK, Smyrnis L, Tai G. Selective infection of astrocytes in human glial cell cultures by rubella virus. Laboratory investigation; a journal of technical methods and pathology 1995. link 28 Lee JY, Marshall JA, Bowden DS. Characterization of rubella virus replication complexes using antibodies to double-stranded RNA. Virology 1994. link 29 Urade M, Mima T, Yamamoto N. Structural gene products and morphogenesis of a hybrid between rubella virus and a hamster latent retrovirus. Research in virology 1993. link80021-x) 30 Chaye H, Ou D, Chong P, Gillam S. Human T- and B-cell epitopes of E1 glycoprotein of rubella virus. Journal of clinical immunology 1993. link 31 Baron MD, Ebel T, Suomalainen M. Intracellular transport of rubella virus structural proteins expressed from cloned cDNA. The Journal of general virology 1992. link 32 Ilonen J, Seppänen H, Närvänen A, Korkolainen M, Salmi AA. Recognition of synthetic peptides with sequences of rubella virus E1 polypeptide by antibodies and T lymphocytes. Viral immunology 1992. link 33 Komatsu H, Suzuki Y, Matumoto M. Double antibody sandwich ELISA for the detection of rubella virus antigen. The Kitasato archives of experimental medicine 1992. link 34 Hossain A. Seroepidemiology of rubella in Saudi Arabia. Journal of tropical pediatrics 1989. link 35 Scalia G, Gerna G, Halonen PE. Detection of rubella virus antigen by one-step time-resolved fluoroimmunoassay and by enzyme immunoassay. Journal of medical virology 1989. link 36 de Mazancourt A, Perricaudet M. Expression of rubella virus cDNA encoding the E1 structural protein. Biochimie 1989. link90162-4) 37 Chu SY, Bernier RH, Stewart JA, Herrmann KL, Greenspan JR, Henderson AK et al.. Rubella antibody persistence after immunization. Sixteen-year follow-up in the Hawaiian Islands. JAMA 1988. link 38 Arista S, Pistoia D, Titone L, Ammatuna P. Comparison of serological methods for the detection of IgG and IgM antibodies to rubella virus. Microbiologica 1987. link 39 Chernesky MA, Smaill F, Mahony JB, Castriciano S. Combined testing for antibodies to rubella non-structural and envelope proteins sentinels infections in two outbreaks. Diagnostic microbiology and infectious disease 1987. link90168-4) 40 Gerna G, Revello MG, Dovis M, Petruzzelli E, Achilli G, Percivalle E et al.. Synergistic neutralization of rubella virus by monoclonal antibodies to viral haemagglutinin. The Journal of general virology 1987. link 41 Enders G, Knotek F. Comparison of the performance and reproducibility of various serological methods and diagnostic kits for the detection of rubella antibodies. Journal of virological methods 1985. link90119-3) 42 Umino Y, Sato TA, Katow S, Matsuno T, Sugiura A. Monoclonal antibodies directed to E1 glycoprotein of rubella virus. Archives of virology 1985. link 43 Vejtorp M. Enzyme-linked immunosorbent assay for determination of rubella IgG antibodies. Acta pathologica et microbiologica Scandinavica. Section B, Microbiology 1978. link

Meningoencephalitis caused by Rubella virus